CANbridge Pharmaceuticals Inc., a Beijing, China-based biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, completed a US$98m Series D financing.
Mastercard (NYSE: MA) has received in-principle approval from the People’s Bank of China (PBOC) to begin formal preparations to set up a domestic bankcard clearing institution in China.
Today’s internet industry ranks as one of the highest-grossing businesses for global players. China is on the mainstream of digital technology as the country is at the forefront of the tech players around the world. Getting ahead of the industry requires business people to stay on top of their game by maximizing their professional value. […]
Adagene, Inc., a Chinese clinical-stage oncology immunotherapy company, completed a $69m Series D financing.
Unicorn Capital Partners, a venture capital fund-of-funds manager, raised Unicorn Capital Partners Fund III, L.P., which closed at US$350M.
Hesai, a Chinese LiDAR technology manufacturer, closed its series C funding totaling USD173M.
CF PharmTech, Inc., a Shuzhou, China-based pharmaceutical company, raised $90m in Series E funding.
AInnovation, a Beijing, China-based AI solutions provider, closed a Series B financing round of nearly 400m yuan (approx. US$60m).
Hotnest Technology, a China – Germany based AI Marketing and Consulting Automation Platform, raised US$6M in Series A funding.
Sequoia Capital, a Menlo Park, California-based venture capital firm, raised nearly 3.4 billion dollars for two funds investing in later-stage U.S. companies, and venture and growth investments in China.
Loyal Valley Capital closed its second US dollar-denominated fund, Loyal Valley Capital Advantage Fund II LP, at $465m.
Reorg, a NYC-based financial media and technology company, acquired Dai1 Media, a subscription-based provider of news, insights and analysis about special situations in China.
Chongqing iQIYI Intelligence Technology Co., Ltd., incubated and operated by iQIYI Inc., a Beijing, China-based online entertainment service, completed an RMB 100 million Series A financing.
Clover Biopharmaceuticals, a Chengdu, China-based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, closed a US$ 43m (RMB 304m) Series B financing.
Lynk, a “Knowledge-as-a-Service” (KaaS) company, closed a funding round of undisclosed amount.